Gastric Cancer
Dr. Cytryn summarizes a trial in progress investigating a novel immunotherapy combination for gastroesophageal adenocarcinoma
Patients with locally advanced GC who achieved pCR after NAC had significantly better survival outcomes.
The panel discusses considerations around treating peritoneal gastric cancer, including the role of HIPEC.
In part three of their discussion, the panel explores the role of ADCs in treating gastric and esophageal cancers.
The panelists discuss the impact of biomarkers on personalized gastric cancer care, including ctDNA, claudin 18.2, and PD-L1.
An expert panel of GI oncologists debates recent advancements in biomarker-driven strategies for GI cancer care.
ASPEN-06 analyzed the CD47 myeloid checkpoint inhibitor ALX148 in patients with HER2-overexpressing gastric cancer.
Dr. Cytryn reviews the FDA approval of tislelizumab and shares thoughts on its clinical impact.
A recent study reviewed global disparities in gastric cancer screening, finding limited research about screening feasibility.
Tislelizumab is a monoclonal antibody with a high affinity and binding specificity against programmed cell death protein 1.
Advertisement
Roundtables
The panel discusses considerations around treating peritoneal gastric cancer, including the role of HIPEC.
In part three of their discussion, the panel explores the role of ADCs in treating gastric and esophageal cancers.
The panelists discuss the impact of biomarkers on personalized gastric cancer care, including ctDNA, claudin 18.2, and PD-L1.
An expert panel of GI oncologists debates recent advancements in biomarker-driven strategies for GI cancer care.
Advertisement
Expert Interviews on GI Oncology
Advertisement
Section Editor
Samuel Cytryn, MDGastrointestinal Medical Oncologist | Memorial Sloan Kettering Cancer Center
Advertisement
Latest GI Oncology News
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.